Tilray Brands Inc TLRY

Alternate Symbol(s): T.TLRY

Healthcare Cannabis

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.

NDAQ:TLRY - Post by User

Tilray Brands Inc > Q4, ending of DEA public comment will see July climb

<< Previous

Bullboard Posts

Next >>

Comment by quinlashon Jun 26, 2024 11:21pm

37 Views

Post# 36108269

RE:Q4, ending of DEA public comment will see July climb

Tradinghands wrote: Q3 was solid and Q4 will end the year on a hgih note. July will bring excitement into the cannabis market as we pass midpoint of this year. Tilray book value is $3.32B and its only trading at a marketcap of $1.40B so huge room to trade upside. Going long!

Achieved Net Revenue of $188 Million, ~ 30% Net Revenue Growth Over the Prior Year Quarter

Beverage-Alcohol Net Revenue Increases 165% Over the Prior Year Quarter, 5th Largest Craft Beer Brewer in the U.S.1 with 4.5% Craft Beer Market Share

Global Cannabis Net Revenue Increases 33% with International Cannabis Growth of 44% Over the Prior Year Quarter, #1 Market Share in Canada and #1 Market Share in Germany

U.S. Cannabis Strategy in Place to Strike with Potential Drug Policy Reform